Preoperative Plasma Club (Clara) Cell Secretory Protein Levels Are Associated With Primary Graft Dysfunction After Lung Transplantation
dc.contributor.author | Shah, R. J. | en_US |
dc.contributor.author | Wickersham, N. | en_US |
dc.contributor.author | Lederer, D. J. | en_US |
dc.contributor.author | Palmer, S. M. | en_US |
dc.contributor.author | Cantu, E. | en_US |
dc.contributor.author | Diamond, J. M. | en_US |
dc.contributor.author | Kawut, S. M. | en_US |
dc.contributor.author | Lama, V. N. | en_US |
dc.contributor.author | Bhorade, S. | en_US |
dc.contributor.author | Crespo, M. | en_US |
dc.contributor.author | Demissie, E. | en_US |
dc.contributor.author | Sonett, J. | en_US |
dc.contributor.author | Wille, K. | en_US |
dc.contributor.author | Orens, J. | en_US |
dc.contributor.author | Weinacker, A. | en_US |
dc.contributor.author | Shah, P. | en_US |
dc.contributor.author | Arcasoy, S. | en_US |
dc.contributor.author | Wilkes, D. S. | en_US |
dc.contributor.author | Christie, J. D. | en_US |
dc.contributor.author | Ware, L. B. | en_US |
dc.date.accessioned | 2014-02-11T17:57:15Z | |
dc.date.available | 2015-04-01T19:59:07Z | en_US |
dc.date.issued | 2014-02 | en_US |
dc.identifier.citation | Shah, R. J.; Wickersham, N.; Lederer, D. J.; Palmer, S. M.; Cantu, E.; Diamond, J. M.; Kawut, S. M.; Lama, V. N.; Bhorade, S.; Crespo, M.; Demissie, E.; Sonett, J.; Wille, K.; Orens, J.; Weinacker, A.; Shah, P.; Arcasoy, S.; Wilkes, D. S.; Christie, J. D.; Ware, L. B. (2014). "Preoperative Plasma Club (Clara) Cell Secretory Protein Levels Are Associated With Primary Graft Dysfunction After Lung Transplantation." American Journal of Transplantation 14(2): 446-452. | en_US |
dc.identifier.issn | 1600-6135 | en_US |
dc.identifier.issn | 1600-6143 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/102697 | |
dc.description.abstract | Inherent recipient factors, including pretransplant diagnosis, obesity and elevated pulmonary pressures, are established primary graft dysfunction (PGD) risks. We evaluated the relationship between preoperative lung injury biomarkers and PGD to gain further mechanistic insight in recipients. We performed a prospective cohort study of recipients in the Lung Transplant Outcomes Group enrolled between 2002 and 2010. Our primary outcome was Grade 3 PGD on Day 2 or 3. We measured preoperative plasma levels of five biomarkers (CC‐16, sRAGE, ICAM‐1, IL‐8 and Protein C) that were previously associated with PGD when measured at the postoperative time point. We used multivariable logistic regression to adjust for potential confounders. Of 714 subjects, 130 (18%) developed PGD. Median CC‐16 levels were elevated in subjects with PGD (10.1 vs. 6.0, p < 0.001). CC‐16 was associated with PGD in nonidiopathic pulmonary fibrosis (non‐IPF) subjects (OR for highest quartile of CC‐16: 2.87, 95% CI: 1.37, 6.00, p = 0.005) but not in subjects with IPF (OR 1.38, 95% CI: 0.43, 4.45, p = 0.59). After adjustment, preoperative CC‐16 levels remained associated with PGD (OR: 3.03, 95% CI: 1.26, 7.30, p = 0.013) in non‐IPF subjects. Our study suggests the importance of preexisting airway epithelial injury in PGD. Markers of airway epithelial injury may be helpful in pretransplant risk stratification in specific recipients. The authors demonstrate a relationship between perioperative CC‐16 blood levels and an increased risk of primary lung allograft dysfunction, particularly in those without idiopathic pulmonary fibrosis as a pretransplant diagnosis. | en_US |
dc.publisher | Wiley Periodicals, Inc. | en_US |
dc.subject.other | Lung Transplantation | en_US |
dc.subject.other | Primary Graft Dysfunction | en_US |
dc.subject.other | CC‐16 | en_US |
dc.subject.other | Acute Lung Injury | en_US |
dc.subject.other | Biomarkers | en_US |
dc.title | Preoperative Plasma Club (Clara) Cell Secretory Protein Levels Are Associated With Primary Graft Dysfunction After Lung Transplantation | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Medicine (General) | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/102697/1/ajt12541.pdf | |
dc.identifier.doi | 10.1111/ajt.12541 | en_US |
dc.identifier.source | American Journal of Transplantation | en_US |
dc.identifier.citedreference | Christie JD, Kotloff RM, Ahya VN, et al. The effect of primary graft dysfunction on survival after lung transplantation. Am J Respir Crit Care Med 2005; 171: 1312 – 1316. | en_US |
dc.identifier.citedreference | Christie JD, Bavaria JE, Palevsky HI, et al. Primary graft failure following lung transplantation. Chest 1998; 114: 51 – 60. | en_US |
dc.identifier.citedreference | Covarrubias M, Ware LB, Kawut SM, et al. Plasma intercellular adhesion molecule‐1 and von Willebrand factor in primary graft dysfunction after lung transplantation. Am J Transplant 2007; 7: 2573 – 2578. | en_US |
dc.identifier.citedreference | Christie JD, Kotloff RM, Pochettino A, et al. Clinical risk factors for primary graft failure following lung transplantation. Chest 2003; 124: 1232 – 1241. | en_US |
dc.identifier.citedreference | Christie JD, Carby M, Bag R, et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction Part II: Definition. A consensus statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2005; 24: 1454 – 1459. | en_US |
dc.identifier.citedreference | Panwar R, Venkatesh B, Kruger P, et al. Plasma protein C levels in immunocompromised septic patients are significantly lower than immunocompetent septic patients: A prospective cohort study. J Hematol Oncol 2009; 2: 43. | en_US |
dc.identifier.citedreference | Jorens PG, Sibille Y, Goulding NJ, et al. Potential role of Clara cell protein, an endogenous phospholipase A2 inhibitor, in acute lung injury. Eur Respir J 1995; 8: 1647 – 1653. | en_US |
dc.identifier.citedreference | Seam N, Meduri GU, Wang H, et al. Effects of methylprednisolone infusion on markers of inflammation, coagulation, and angiogenesis in early acute respiratory distress syndrome. Crit Care Med 2012; 40: 495 – 501. | en_US |
dc.identifier.citedreference | Pires‐Neto RC, Morales MMB, Lancas T, et al. Expression of acute‐phase cytokines, surfactant proteins, and epithelial apoptosis in small airways of human acute respiratory distress syndrome. J Crit Care 2013; 28: 111.e9 – 111.e15. | en_US |
dc.identifier.citedreference | Thomsen M, Ingebrigtsen TS, Marott JL, et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. J Am Med Assoc 2013; 309: 2353 – 2361. | en_US |
dc.identifier.citedreference | Sims MW, Beers MF, Ahya VN, et al. Effect of single vs bilateral lung transplantation on plasma surfactant protein D levels in idiopathic pulmonary fibrosis. Chest 2011; 140: 489 – 496. | en_US |
dc.identifier.citedreference | Kropski JA, Fremont RD, Calfee CS, Ware LB. Clara cell protein (CC16), a marker of lung epithelial injury, is decreased in plasma and pulmonary edema fluid from patients with acute lung injury. Chest 2009; 135: 1440 – 1447. | en_US |
dc.identifier.citedreference | Lesur O, Langevin S, Berthiaume Y, et al. Outcome value of Clara cell protein in serum of patients with acute respiratory distress syndrome. Intensive Care Med 2006; 32: 1167 – 1174. | en_US |
dc.identifier.citedreference | Janssen R, Sato H, Grutters JC, et al. Study of Clara cell 16, KL‐6, and surfactant protein‐D in serum as disease markers in pulmonary sarcoidosis. Chest 2003; 124: 2119 – 2125. | en_US |
dc.identifier.citedreference | Broeckaert F, Clippe A, Knoops B, Hermans C, Bernard A. Clara cell secretory protein (CC16): Features as a peripheral lung biomarker. Ann N Y Acad Sci 2000; 923: 68 – 77. | en_US |
dc.identifier.citedreference | Sterne JA, White IR, Carlin JB, et al. Multiple imputation for missing data in epidemiological and clinical research: Potential and pitfalls. BMJ 2009; 338: 157 – 160. | en_US |
dc.identifier.citedreference | Shah RJ, Diamond JM, Cantu E, et al. Use of a simple prediction model improves pre‐transplant risk stratification for primary graft dysfunction after lung transplantation. Am J Respir Crit Care Med 2013; 187: A3773. | en_US |
dc.identifier.citedreference | Maldonado G, Greenland S. Simulation study of confounder‐selection strategies. Am J Epidemiol 1993; 138: 923 – 936. | en_US |
dc.identifier.citedreference | Lederer DJ, Kawut SM, Wickersham N, et al. Obesity and primary graft dysfunction after lung transplantation: The Lung Transplant Outcomes Group Obesity Study. Am J Respir Crit Care Med 2011; 184: 1055 – 1061. | en_US |
dc.identifier.citedreference | Royston P, Ambler G, Sauerbrei W. The use of fractional polynomials to model continuous risk variables in epidemiology. Int J Epidemiol 1999; 28: 964 – 974. | en_US |
dc.identifier.citedreference | Hermans C, Petrek M, Kolek V, et al. Serum Clara cell protein (CC16), a marker of the integrity of the air‐blood barrier in sarcoidosis. Eur Respir J 2001; 18: 507 – 514. | en_US |
dc.identifier.citedreference | Hoffman SA, Wang L, Shah CV, et al. Plasma cytokines and chemokines in primary graft dysfunction post‐lung transplantation. Am J Transplant 2009; 9: 389 – 396. | en_US |
dc.identifier.citedreference | Lee JC, Christie JD. Primary graft dysfunction. Proc Am Thorac Soc 2009; 6: 39 – 46. | en_US |
dc.identifier.citedreference | Cypel M, Yeung JC, Liu M, et al. Normothermic ex vivo lung perfusion in clinical lung transplantation. N Engl J Med 2011; 364: 1431 – 1440. | en_US |
dc.identifier.citedreference | Department of Health and Human Services HRaSA, Healthcare Systems Bureau, Division of Transplantation, Rockville, MD; United Network for Organ Sharing, Richmond, VA. 2012. Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients. Transplant Data 1994–2012. 2012. | en_US |
dc.identifier.citedreference | Diamond JM, Lee JC, Kawut SM, et al. Clinical risk factors for primary graft dysfunction after lung transplantation. Am J Respir Crit Care Med 2013; 187: 527 – 534. | en_US |
dc.identifier.citedreference | Shah RJ, Bellamy SL, Localio AR, et al. A panel of lung injury biomarkers enhances the definition of primary graft dysfunction (PGD) after lung transplantation. J Heart Lung Transplant 2012; 31: 942 – 949. | en_US |
dc.identifier.citedreference | Diamond JM, Kawut SM, Lederer DJ, et al. Elevated plasma Clara cell secretory protein concentration is associated with high‐grade primary graft dysfunction. Am J Transplant 2011; 11: 561 – 567. | en_US |
dc.identifier.citedreference | Christie JD, Shah CV, Kawut SM, et al. Plasma levels of receptor for advanced glycation end products, blood transfusion, and risk of primary graft dysfunction. Am J Respir Crit Care Med 2009; 180: 1010 – 1015. | en_US |
dc.identifier.citedreference | Christie JD, Robinson N, Ware LB, et al. Association of protein C and type 1 plasminogen activator inhibitor with primary graft dysfunction. Am J Respir Crit Care Med 2007; 175: 69 – 74. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.